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Introduction
Anti-TNFa treatment has become an important part of
our systemic treatment in chronic inflammatory arthri-
tis. Local application to the joint produces transient
clinical improvement since the drug quickly leaves the
joint.
Objectives
We aimed to develop a sustained release system for an
anti-TNFa drug in treatment of chronic inflammatory
arthritis. A novel form of intra-articularly injectable eta-
nercept (ETN) loaded poly(ε-caprolactone) (PCL) or
methoxy poly(ethylene glycol)-poly(ε-caprolactone)-
methoxy poly(ethylene glycol) (MPEG-PCL-MPEG)
microspheres (patent pending) were prepared to provide
long term controlled release of ETN with a sustained
anti-inflammatory effect as a local treatment approach.
Methods
Size, surface morphology, encapsulation efficiency, and
in vitro release profiles of g-sterilized microspheres
loaded with ETN were determined. Treatment efficacies
of free and microsphere loaded ETN were evaluated by
determining changes in cell number and viability of
fibroblast-like synoviocytes (FLS), in protein levels of
pro-inflammatory cytokines (TNFa, IL-6, IFNg, IL-17)
and MMPs (MMP-3 and MMP-13) and in mRNA
expressions of TNFa, IL-6, MMP-3 and MMP-13.
Results
Microspheres possessed a rough surface and had a mean
particle size around 5 μm. MPEG-PCL-MPEG micro-
spheres had higher drug encapsulation efficiency than
PCL microspheres. Total amounts of biologically active
ETN released from MPEG-PCL-MPEG microspheres
were significantly higher than that from PCL micro-
spheres at each time point during the four weeks study
period. FLS viability significantly decreased in the free
drug group at first week whereas no significant decrease
was observed in microsphere groups. ETN loaded
microspheres significantly decreased the levels of pro-
inflammatory cytokines TNFa, IL-6, IFNg, IL-17 and
MMPs in FLSs. However, there were no significant var-
iations in the gene expressions of pro-inflammatory
cytokines and MMPs among groups.
Conclusion
ETN loaded microspheres provide a sustained release,
which resulted with a significant decrease in pro-inflam-
matory cytokines and MMPs levels. This study showed
that MPEG-PCL-MPEG and PCL microspheres are pro-
mising and safe systems for an effective local treatment
approach in chronic inflammatory arthritis.
This study is a part of patent pending invention (PCT
No: PCT/TR2012/000148).
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